| Journal: | Annals of hepatology |
| Database: | PERIÓDICA |
| System number: | 000409348 |
| ISSN: | 1665-2681 |
| Authors: | Varghese, Joy1 Kumar Kedarisetty, Chandan1 Venkataraman, Jayanthi1 Srinivasan, Vijaya1 Deepashree, Thiruchunapalli1 Chinnappa Uthappa, Mangerira1 Ilankumaran, Kaliamurthy1 Govil, Sanjay1 Srinivas Reddy, Mettu1 Rela, Mohamed1 |
| Institutions: | 1Institute of Liver Diseases and Transplantation, Global Health city, Chennai, Tamil Nadu. India |
| Year: | 2017 |
| Season: | Mar-Abr |
| Volumen: | 16 |
| Number: | 2 |
| Pages: | 247-2 |
| Country: | México |
| Language: | Inglés |
| Document type: | Estadística o encuesta |
| Approach: | Analítico |
| English abstract | Transarterial chemoembolization (TACE) or sorafenib is recommended for hepatocellular carcinoma BCLC stages B and C respectively. We studied the role of combination of TACE and sorafenib in BCLC stages B/C. Material and methods. methods. We undertook an observational study on a cohort of cirrhotics with HCC from August 2010 through October 2014. Patients in BCLC stages B/C who had received TACE and/or sorafenib were included. mRECIST criteria were used to assess tumor response. The primary end point was overall survival. Results. Results. Out Results. of 124 patients, 47.6% were in BCLC-B and 52.4% in BCLCC. Baseline characteristics were comparable. The predominant etiology was cryptogenic (37.2% and 38.5%, p = NS). 49.1% in BCLC-B and 56.9% in BCLC-C had received TACE+sorafenib. In BCLC-B, the overall survival improved from 9 months (95% CI 6.3-11.7) using TACE only to 16 months (95% CI 12.9-19.1) using TACE+sorafenib (p < 0.05). In BCLC-C, addition of TACE to sorafenib improved the overall survival from 4 months (95%CI 3-5) to 9 months (95%CI 6.8-11.2) (p < 0.0001). As per mRECIST criteria, patients on TACE+sorafenib had reduced progressive disease (37.8% vs. 83.3%), improved partial response (43.2% vs. 3.3%) and one had complete response compared to those on sorafenib alone (p < 0.0001) in BCLC-C but not in BCLC-B group. Hand foot syndrome was noted in 27.7% patients on sorafenib and post TACE syndrome in 80.2% patients, but both were reversible. No major adverse events were noted. Conclusion. TACE+sorafenib was more effective than TACE or sorafenib alone in HCC BCLC stages B or C with a significant survival benefit and improved tumour regression especially in BCLC-C patients |
| Disciplines: | Medicina |
| Keyword: | Gastroenterología, Oncología, Terapéutica y rehabilitación, Hepatoma, Fibrosis, Hígado, Trasplantes, Cuidados paliativos |
| Keyword: | Medicine, Gastroenterology, Oncology, Therapeutics and rehabilitation, Hepatoma, Fibrosis, Liver, Transplantation, Palliative care |
| Full text: | Texto completo (Ver PDF) |
